Literature DB >> 15221148

[Isoforms of free prostate-specific antigen].

A Haese1, J Noldus, T Steuber, H Huland, H Lilja.   

Abstract

Detection of prostate-specific antigen remains the mainstay in the early detection of prostate cancer. A problem yet unsolved is the lack of specificity of this organ- but not cancer-specific marker, which generates subsequent, invasive procedures in a high number of patients without detecting prostate cancer. While the separate detection of free PSA and the ratio of free to total PSA has significantly improved specificity while maintaining high sensitivity, the number of patients undergoing unnecessary further diagnostics is still of concern. In this context, the evolving knowledge on isoforms of free PSA is a major focus of current research. Isoforms of free PSA are variants of free PSA that circulate, e.g., as precursor forms, internally cleaved variants of intact molecules, and are suggested to be either more associated with cancer or more with benign diseases. This article describes biochemical and clinical properties of the isoforms of free PSA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221148     DOI: 10.1007/s00120-004-0584-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  36 in total

1.  Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer.

Authors:  J Noldus; Z Chen; T A Stamey
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

2.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

3.  Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells.

Authors:  A Kumar; S D Mikolajczyk; T M Hill; L S Millar; M S Saedi
Journal:  Prostate       Date:  2000-08-01       Impact factor: 4.104

4.  A prostate antigen in sera of prostatic cancer patients.

Authors:  L D Papsidero; M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

5.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

6.  Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms.

Authors:  A Herrala; R Kurkela; M Vihinen; N Kalkkinen; P Vihko
Journal:  Eur J Biochem       Date:  1998-07-15

7.  Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.

Authors:  A Bélanger; H van Halbeek; H C Graves; K Grandbois; T A Stamey; L Huang; I Poppe; F Labrie
Journal:  Prostate       Date:  1995-10       Impact factor: 4.104

8.  Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

Authors:  Theresa Y Chan; Stephen D Mikolajczyk; Kristin Lecksell; Matthew J Shue; Harry G Rittenhouse; Alan W Partin; Jonathan I Epstein
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

9.  Complex formation between PSA isoenzymes and protease inhibitors.

Authors:  J Leinonen; W M Zhang; U H Stenman
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

10.  Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.

Authors:  Harry J Linton; Leonard S Marks; Lisa S Millar; Christine L Knott; Harry G Rittenhouse; Stephen D Mikolajczyk
Journal:  Clin Chem       Date:  2003-02       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.